Dr. Lal PathLabs Limited (BOM:539524)
India · Delayed Price · Currency is INR | Market Cap | 321.55B +22.4% |
| Revenue (ttm) | 28.91B +14.3% |
| Net Income | 5.42B +5.6% |
| EPS | 32.40 +5.4% |
| Shares Out | n/a |
| PE Ratio | 59.28 |
| Forward PE | 49.32 |
| Dividend | 16.00 (0.83%) |
| Ex-Dividend Date | Jul 30, 2026 |
| Volume | 6,958 |
| Open | 1,890.00 |
| Previous Close | 1,902.30 |
| Day's Range | 1,879.05 - 1,935.05 |
| 52-Week Range | 1,272.00 - 2,035.00 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 2,018.08 (+5.07%) |
| Earnings Date | Nov 4, 2026 |
About Dr. Lal PathLabs
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India. [Read more]
Financial Performance
In fiscal year 2026, Dr. Lal PathLabs's revenue was 27.63 billion, an increase of 12.25% compared to the previous year's 24.61 billion. Earnings were 5.05 billion, an increase of 3.62%.
Financial StatementsAnalyst Summary
According to 26 analysts, the average rating for 539524 stock is "Buy." The 12-month stock price target is ₹2,018, which is an increase of 5.07% from the latest price.
News
Dr. Lal PathLabs Transcript: Q1 26/27
Q1 FY27 saw 19.1% revenue growth, driven by higher patient volumes, improved realizations, and strong Swasthfit and Suburban performance. EBITDA margin reached 31%, with robust cash reserves and continued investment in innovation and expansion.
Dr. Lal PathLabs Quarterly report: Q1 2027
Dr. Lal PathLabs has published its Q1 2027 quarterly earnings report on July 24, 2026.
Dr. Lal PathLabs Slides: Q1 2027
Dr. Lal PathLabs has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on July 24, 2026.
India's Dr Lal PathLabs posts higher first-quarter profit on healthy demand for tests
Indian diagnostics firm Dr Lal PathLabs on Friday reported a rise in first-quarter profit, boosted by sustained demand for its tests and preventive health packages under the SwasthFit banner.
Dr. Lal PathLabs Earnings Call Transcript: Q4 2026
FY 2026 saw double-digit revenue and EBITDA growth, driven by volume gains, network expansion, and strong B2C performance. Outlook for FY 2027 is early to mid-teens revenue growth with stable margins, supported by continued investment and broad-based regional momentum.
Dr. Lal PathLabs Quarterly report: Q4 2026
Dr. Lal PathLabs has published its Q4 2026 quarterly earnings report on April 30, 2026.
Dr. Lal PathLabs Slides: Q4 2026
Dr. Lal PathLabs has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on April 30, 2026.
Dr. Lal PathLabs Annual report: Q4 2026
Dr. Lal PathLabs has published its Q4 2026 annual report on April 30, 2026.
Dr Lal PathLabs records Rs 703 Cr revenue with 16.6% growth in Q4 FY26
Dr Lal PathLabs Limited, a prominent diagnostic and healthcare service provider, has announced its financial results for the quarter ending March 31, 2026. The company reported a revenue of ₹703…
Dr Lal Pathlabs Q4 Results: Profit falls 15% as margin declines nearly 300 bps
Dr Lal PathLabs reported a decline in profitability for the quarter ended March 31, 2026, even as revenue posted steady growth. Revenue from operations rose 16.60% year-on-year (YoY) to ₹702.70…
Petronet LNG, HDFC Bank & more: Top stocks to watch today
Nomura cut Petronet LNG's target price due to West Asia crisis impacting volumes, while HSBC maintained a hold on Blue Star, citing demanding valuations. BofA Securities remains constructive on HDFC B...
Dr Lal PathLabs share in focus as CLSA sees ~17% upside on volume-led growth
Shares of Dr Lal PathLabs are in focus after CLSA maintained an Outperform rating on the stock with a target...
Dr. Lal PathLabs Transcript: Q3 25/26
Revenue grew 10.6% YoY in Q3 FY26, with strong EBITDA margin of 27.2% and robust cash reserves. Preventive health packages and digital innovation drove growth, while a one-time Labour Code cost impacted PAT. Management expects stable margins and organic growth ahead.
Dr. Lal PathLabs Quarterly report: Q3 2026
Dr. Lal PathLabs has published its Q3 2026 quarterly earnings report on January 30, 2026.
Dr. Lal PathLabs Slides: Q3 2026
Dr. Lal PathLabs has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on January 30, 2026.
Dr. Lal PathLabs fixes December 19 as record date for 1:1 bonus issue
Dr. Lal PathLabs Ltd has announced that its Board of Directors has fixed Friday, December 19, 2025, as the record...
Dr. Lal PathLabs Transcript: Q2 25/26
Revenue grew 10.7% YoY in Q2 FY26 with strong profitability and a PAT increase of 16.4%. Investments in digital, AI, and high-end diagnostics, along with disciplined network expansion, are driving growth. Interim dividend and a 1:1 bonus issue were announced.
Dr. Lal PathLabs Quarterly report: Q2 2026
Dr. Lal PathLabs has published its Q2 2026 quarterly earnings report on October 31, 2025.
Dr. Lal PathLabs Slides: Q2 2026
Dr. Lal PathLabs has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on October 31, 2025.
Dr Lal PathLabs, Metropolis Healthcare shares decline as Amazon Diagnostics enters market
Shares of diagnostic service providers Dr Lal PathLabs and Metropolis Healthcare slipped in Monday’s trade following Amazon India’s announcement of its foray into the diagnostics space. Amazon launche...
Dr Lal PathLabs shares decline 2% as Amazon enters diagnostics segment with doorstep lab tests
Shares of Dr Lal PathLabs fell over 2% to Rs 2,849.00 on Monday after Amazon India announced the launch of its diagnostics service in collaboration with Orange Health Labs. The new offering is expecte...
Dr. Lal PathLabs Q4 FY25: Revenue up 10.48% to 602.6 crore, Net profit surges 81% YoY
Dr. Lal PathLabs Ltd reported a strong financial performance for the fourth quarter ended March 31, 2025, with consolidated net profit rising 81% year-on-year to ₹155.5 crore, up from ₹85.8 crore in Q...